REGITINE- phentolamine mesylate injection, powder, lyophilized, for suspension
Novartis Pharmaceuticals Corporation

----------

Regitine®

C98-25
665490

Regitine®
phentolamine mesylate for injection, USP
Vials
Rx only
Prescribing Information

DESCRIPTION
Regitine, phentolamine mesylate for injection, USP, is an antihypertensive, available in vials for intravenous and intramuscular administration. Each vial contains phentolamine mesylate USP, 5 mg, and mannitol USP, 25 mg, in sterile, lyophilized form.

Phentolamine mesylate is 4,5-dihydro-2-[N-(m-hydroxyphenyl)-N-(p-methylphenyl) aminomethyl]-1H-imidazole 1:1 methanesulfonate, and its structural formula is

Phentolamine mesylate for injection, USP, is a white or off-white, odorless crystalline powder with a molecular weight of 377.46. Its solutions are acid to litmus. It is freely soluble in water and in alcohol, and slightly soluble in chloroform. It melts at about 178°C.

CLINICAL PHARMACOLOGY
Regitine produces an alpha-adrenergic block of relatively short duration. It also has direct, but less marked, positive inotropic and chronotropic effects on cardiac muscle and vasodilator effects on vascular smooth muscle.

Regitine has a half-life in the blood of 19 minutes following intravenous administration. Approximately 13% of a single intravenous dose appears in the urine as unchanged drug.

INDICATIONS AND USAGE
Regitine is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision.

Regitine is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine.

Regitine is also indicated for the diagnosis of pheochromocytoma by the Regitine blocking test.
CONTRAINDICATIONS
Myocardial infarction, history of myocardial infarction, coronary insufficiency, angina, or other
evidence suggestive of coronary artery disease; hypersensitivity to phentolamine or related compounds.

WARNINGS
Myocardial infarction, cerebrovascular spasm, and cerebrovascular occlusion have been reported to
occur following the administration of Regitine, usually in association with marked hypotensive
episodes.

For screening tests in patients with hypertension, the generally available urinary assay of
catecholamines or other biochemical assays have largely replaced the Regitine and other
pharmacological tests for reasons of accuracy and safety. None of the chemical or pharmacological
tests is infallible in the diagnosis of pheochromocytoma. The Regitine blocking test is not the
procedure of choice and should be reserved for cases in which additional confirmatory evidence is
necessary and the relative risks involved in conducting the test have been considered.

PRECAUTIONS

General
Tachycardia and cardiac arrhythmias may occur with the use of Regitine or other alpha-adrenergic
blocking agents. When possible, administration of cardiac glycosides should be deferred until cardiac
rhythm returns to normal.

Drug Interactions
See DOSAGE AND ADMINISTRATION, Diagnosis of pheochromocytoma, Preparation.

Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term carcinogenicity studies, mutagenicity studies, and fertility studies have not been conducted
with Regitine.

Pregnancy Category C
Administration of Regitine to pregnant rats and mice at oral doses 24-30 times the usual daily human
dose (based on a 60-kg human) resulted in slightly decreased growth and slight skeletal immaturity of
the fetuses. Immaturity was manifested by increased incidence of incomplete or unossified calcanei and
phalangeal nuclei of the hind limb and of incompletely ossified sternebrae. At oral doses 60 times the
usual daily human dose (based on a 60-kg human), a slightly lower rate of implantation was found in the
rat. Regitine did not affect embryonic or fetal development in the rabbit at oral doses 20 times the usual
daily human dose (based on a 60-kg human). No teratogenic or embryotoxic effects were observed in
the rat, mouse, or rabbit studies.

There are no adequate and well-controlled studies in pregnant women. Regitine should be used during
pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human
milk and because of the potential for serious adverse reactions in nursing infants from Regitine, a
decision should be made whether to discontinue nursing or to discontinue the drug, taking into account
the importance of the drug to the mother.

Pediatric Use
ADVERSE REACTIONS
Acute and prolonged hypotensive episodes, tachycardia, and cardiac arrhythmias have been reported. In addition, weakness, dizziness, flushing, orthostatic hypotension, nasal stuffiness, nausea, vomiting, and diarrhea may occur.

OVERDOSAGE

Acute Toxicity
No deaths due to acute poisoning with Regitine have been reported.
Oral LD_{50}'s (mg/kg): mice, 1000; rats, 1250.

Signs and Symptoms
Overdosage with Regitine is characterized chiefly by cardiovascular disturbances, such as arrhythmias, tachycardia, hypotension, and possibly shock. In addition, the following might occur: excitation, headache, sweating, pupillary contraction, visual disturbances; nausea, vomiting, diarrhea; hypoglycemia.

Treatment
There is no specific antidote.

A decrease in blood pressure to dangerous levels or other evidence of shocklike conditions should be treated vigorously and promptly. The patient’s legs should be kept raised and a plasma expander should be administered. If necessary, intravenous infusion of norepinephrine, titrated to maintain blood pressure at the normotensive level, and all available supportive measures should be included. Epinephrine should not be used, since it may cause a paradoxical reduction in blood pressure.

DOSAGE AND ADMINISTRATION

The reconstituted solution should be used upon preparation and should not be stored.

Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

1. Prevention or control of hypertensive episodes in the patient with pheochromocytoma.
For preoperative reduction of elevated blood pressure, 5 mg of Regitine (1 mg for children) is injected intravenously or intramuscularly 1 or 2 hours before surgery, and repeated if necessary.

During surgery, Regitine (5 mg for adults, 1 mg for children) is administered intravenously as indicated, to help prevent or control paroxysms of hypertension, tachycardia, respiratory depression, convulsions, or other effects of epinephrine intoxication. (Postoperatively, norepinephrine may be given to control the hypotension that commonly follows complete removal of a pheochromocytoma.)

2. Prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine.
For Prevention: 10 mg of Regitine is added to each liter of solution containing norepinephrine. The pressor effect of norepinephrine is not affected.

For Treatment: 5-10 mg of Regitine in 10 mL of saline is injected into the area of extravasation within 12 hours.

3. Diagnosis of pheochromocytoma — Regitine blocking test.
The test is most reliable in detecting pheochromocytoma in patients with sustained hypertension and least reliable in those with paroxysmal hypertension. False-positive tests may occur in patients with hypertension without pheochromocytoma.

**a. Intravenous**

**Preparation**

The CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS sections should be reviewed. Sedatives, analgesics, and all other medications except those that might be deemed essential (such as digitalis and insulin) are withheld for at least 24 hours, and preferably 48-72 hours, prior to the test. Antihypertensive drugs are withheld until blood pressure returns to the untreated, hypertensive level. This test is not performed on a patient who is normotensive.

**Procedure**

The patient is kept at rest in the supine position throughout the test, preferably in a quiet, darkened room. Injection of Regitine is delayed until blood pressure is stabilized, as evidenced by blood pressure readings taken every 10 minutes for at least 30 minutes.

Five milligrams of Regitine is dissolved in 1 mL of Sterile Water for Injection. The dose for adults is 5 mg; for children, 1 mg.

The syringe needle is inserted into the vein, and injection is delayed until pressor response to venipuncture has subsided.

Regitine is injected rapidly. Blood pressure is recorded immediately after injection, at 30-second intervals for the first 3 minutes, and at 60-second intervals for the next 7 minutes.

**Interpretation**

A positive response, suggestive of pheochromocytoma, is indicated when the blood pressure is reduced more than 35 mmHg systolic and 25 mmHg diastolic. A typical positive response is a reduction in pressure of 60 mmHg systolic and 25 mmHg diastolic. Usually, maximal effect is evident within 2 minutes after injection. A return to preinjection pressure commonly occurs within 15-30 minutes but may occur more rapidly.

If blood pressure decreases to a dangerous level, the patient should be treated as outlined under OVERDOSAGE.

A positive response should always be confirmed by other diagnostic procedures, preferably by measurement of urinary catecholamines or their metabolites.

A negative response is indicated when the blood pressure is elevated, unchanged, or reduced less than 35 mmHg systolic and 25 mmHg diastolic after injection of Regitine. A negative response to this test does not exclude the diagnosis of pheochromocytoma, especially in patients with paroxysmal hypertension in whom the incidence of false-negative responses is high.

**b. Intramuscular**

If the intramuscular test for pheochromocytoma is preferred, preparation is the same as for the intravenous test. Five milligrams of Regitine is then dissolved in 1 mL of Sterile Water for Injection. The dose for adults is 5 mg intramuscularly; for children, 3 mg. Blood pressure is recorded every 5 minutes for 30-45 minutes following injection. A positive response is indicated when the blood pressure is reduced 35 mmHg systolic and 25 mmHg diastolic, or more, within 20 minutes following injection.

**HOW SUPPLIED**
Vials—each containing 5 mg of phentolamine mesylate for injection, USP, and 25 mg of mannitol, USP, in lyophilized form.
Cartons of 2……………………………………………………………………NDC 0083-6830-02

The reconstituted solution should be used upon preparation and should not be stored.
Store between 15°C and 30°C (59°F-86°F).

665490 C98-25 (Rev. 6/98)

Distributed by
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936

©1998 Novartis

REGITINE

phentolamine mesylate injection, powder, lyophilized, for suspension

Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item Code (Source)</td>
<td>NDC:0083-6830</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>INTRAMUSCULAR, INTRAVENOUS</td>
</tr>
</tbody>
</table>

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>phentolamine mesylate (UNII: Y7543E5K9T) (phentolamine - UNII:Z468598HBV)</td>
<td></td>
<td>5 mg in 1 mL</td>
</tr>
</tbody>
</table>

Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>mannitol (UNII: 3OWL53L36A)</td>
<td>25 mg in 1 mL</td>
</tr>
</tbody>
</table>

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0083-6830-02</td>
<td>2 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>1 mL in 1 VIAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Labeler - Novartis Pharmaceuticals Corporation

Revised: 5/2006